Home » Newsletters » BioWorld Science

BioWorld Science

April 10, 2003

View Archived Issues

Frovatriptan in cluster headache and menstrually associated migraine

New data on alitretinoin and bexarotene in dermatological disorders

Infliximab effective and well tolerated in plaque psoriasis

Adjunctive levetiracetam for pain relief in multiple sclerosis

Use of topiramate in the prevention of migraine attacks

New HIV reverse transcriptase inhibitors in Medivir research pipeline

Another series of angiogenesis inhibitors identified at Merck

Dual LH and FSH receptor agonists discovered at Akzo Nobel

Aminopyrrole p38 kinase inhibitors in early development at Roche

Zentaris researchers prepare and test new antitumor agents

Inotek claims PARP inhibitors with activity in inflammation, reperfusion and diabetes models

New benzothiazepine-based IBAT inhibitors discovered at AstraZeneca

Pharmexa seeks approval in Europe for phase II HER-2 DNA AutoVac trial

Oral phenoxodiol tested in phase II study for skin cancer

Patient dosing under way in new phase IIa trial of dexanabinol

Sunol Molecular initiates trial to combat complications from E. coli infections

COX-2 inhibition as a novel therapeutic approach in Parkinson's disease

Vinorelbine TCS selected for development

Worldwide status of Replagal updated by TKT

Jerini decapeptide designated orphan drug for angioedema

Clinical testing of Tbeta4 begins at RegeneRx

Lilly and Sankyo advance CS-747 to phase II

Choongwae will market mitiglinide in Korea

First-in-man study of Probiodrug DPP-IV inhibitor

ASCOT data demonstrate significant cardiovascular benefits for Lipitor

NDA filed for Tracleer in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...